Literature DB >> 16473827

The calcineurin phosphatase complex modulates immunogenic B cell responses.

Monte M Winslow1, Elena M Gallo, Joel R Neilson, Gerald R Crabtree.   

Abstract

A series of signal-directed transitions regulates the development of distinct populations of self-tolerant B cells and ultimately the production of antibody-producing plasma cells. We studied the role of calcineurin/NFAT signaling in B cells by deleting the regulatory b1 subunit of calcineurin specifically in B cells. Follicular (FO) and marginal zone (MZ) B cells develop normally in these mice, but B1 cell numbers are reduced. In vitro, calcineurin b1-deficient B cells have a cell-intrinsic proliferation defect downstream of the B cell receptor. These mice have higher total serum IgM despite the absence of B1 cells and have enhanced T cell-independent-1 responses. Conversely, mice with calcineurin b1-deficient B cells develop larger germinal centers and have reduced plasma cell development and antigen-specific antibody production during T cell-dependent immune responses. By several different criteria, calcineurin is dispensable for B cell tolerance, indicating that this phosphatase complex modulates immunogenic, but not tolerogenic, responses in vivo.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16473827     DOI: 10.1016/j.immuni.2005.12.013

Source DB:  PubMed          Journal:  Immunity        ISSN: 1074-7613            Impact factor:   31.745


  36 in total

Review 1.  NFAT, immunity and cancer: a transcription factor comes of age.

Authors:  Martin R Müller; Anjana Rao
Journal:  Nat Rev Immunol       Date:  2010-08-20       Impact factor: 53.106

2.  A conserved enhancer element differentially regulates developmental expression of CD5 in B and T cells.

Authors:  Robert Berland; Steven Fiering; Henry H Wortis
Journal:  J Immunol       Date:  2010-11-12       Impact factor: 5.422

Review 3.  Effect of Immunosuppressive Drugs on Humoral Allosensitization after Kidney Transplant.

Authors:  Olivier Thaunat; Alice Koenig; Claire Leibler; Philippe Grimbert
Journal:  J Am Soc Nephrol       Date:  2016-02-12       Impact factor: 10.121

4.  Midterm clinico-radiologic findings of an open label observation study of add-on tacrolimus with biologics or non-biologic DMARDs.

Authors:  Yuya Takakubo; Yasunobu Tamaki; Tomoyuki Hirayama; Kiyoshi Iwazaki; Suran Yang; Akiko Sasaki; Haruki Nakano; Yrjö T Konttinen; Michiaki Takagi
Journal:  Rheumatol Int       Date:  2011-11-08       Impact factor: 2.631

5.  Developmentally regulated expression of MEF2C limits the response to BCR engagement in transitional B cells.

Authors:  Sarah F Andrews; Xuezhi Dai; Byoung Y Ryu; Tod Gulick; Bindu Ramachandran; David J Rawlings
Journal:  Eur J Immunol       Date:  2012-05       Impact factor: 5.532

6.  Mzb1 protein regulates calcium homeostasis, antibody secretion, and integrin activation in innate-like B cells.

Authors:  Henrik Flach; Marc Rosenbaum; Marlena Duchniewicz; Sola Kim; Shenyuan L Zhang; Michael D Cahalan; Gerhard Mittler; Rudolf Grosschedl
Journal:  Immunity       Date:  2010-11-24       Impact factor: 31.745

Review 7.  Understanding B-cell tolerance through the use of immunoglobulin transgenic models.

Authors:  Kirthi Raman Kumar; Chandra Mohan
Journal:  Immunol Res       Date:  2008       Impact factor: 2.829

8.  Transcription factor Zfx controls BCR-induced proliferation and survival of B lymphocytes.

Authors:  Teresita L Arenzana; Matthew R Smith-Raska; Boris Reizis
Journal:  Blood       Date:  2009-03-27       Impact factor: 22.113

9.  Transitional B cells exhibit a B cell receptor-specific nuclear defect in gene transcription.

Authors:  Sarah F Andrews; David J Rawlings
Journal:  J Immunol       Date:  2009-03-01       Impact factor: 5.422

10.  Modulation of peripheral B cell tolerance by CD72 in a murine model.

Authors:  Daniel Hsieh-Hsin Li; Monte M Winslow; Thai M Cao; Albert H Chen; Corrine R Davis; Elizabeth D Mellins; Paul J Utz; Gerald R Crabtree; Jane R Parnes
Journal:  Arthritis Rheum       Date:  2008-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.